SCHEDULE: Citadel Discloses 5.3% Stake in Corbus Pharmaceuticals
Beneficial Ownership Disclosure
Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.3% in Corbus Pharmaceuticals Holdings, Inc.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 873,313 shares, representing 4.7% of Corbus Pharmaceuticals' common stock.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 107,297 shares, representing 0.6% of the common stock.
- Kenneth Griffin, through his various affiliations, beneficially owns an aggregate of 980,610 shares, constituting 5.3% of the outstanding common stock.
- The beneficial ownership is primarily held with shared voting and dispositive power.
- The percentages are based on 18,528,517 shares outstanding as of October 30, 2025, according to the issuer's prospectus.
Sentiment
Score: 6
Explanation: The filing is a neutral disclosure of beneficial ownership. The presence of a significant institutional investor like Citadel could be viewed positively by some, but the filing itself contains no performance or forward-looking statements to assess a strong sentiment.
Positives
- A significant institutional investor, Citadel, has disclosed a beneficial ownership stake in Corbus Pharmaceuticals, potentially indicating investor interest.
Future Outlook
NA
Industry Context
This filing reflects a standard disclosure by a major investment firm, Citadel, regarding its passive ownership stake in a publicly traded company. Such disclosures provide transparency on significant institutional holdings, which can be a factor in market sentiment and liquidity for the issuer's stock.
Stakeholder Impact
- Shareholders gain transparency regarding significant institutional ownership, which can influence market perception and trading activity.
- The disclosure confirms that the securities were not acquired for the purpose of changing or influencing control of the issuer, providing stability regarding corporate governance.
Key Dates
| Date | Description |
|---|---|
| 2023-10-13 | Date of power of attorney filing for Seth Levy on behalf of Kenneth Griffin (referenced in filing). |
| 2025-10-30 | Date for which 18,528,517 shares outstanding were reported by the issuer. |
| 2025-11-04 | Date of event which required the filing of this statement. |
| 2025-11-12 | Date of filing of this Schedule 13G statement. |
Keywords
Corbus Pharmaceuticals Holdings Inc., Citadel Advisors LLC, Citadel Securities LLC, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.